Expanded Access for LJPC-501

NCT03245528 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2018-03-08

No results posted yet for this study

Summary

The primary objective of the study is to provide access to LJPC-501 for distributive shock patients who remain hypotensive despite receiving fluid and vasopressor therapy.

Conditions

  • Catecholamine Resistant Hypotension (CRH)
  • Distributive Shock
  • High Output Shock
  • Sepsis
  • Vasodilatory Shock

Interventions

DRUG

LJPC-501

angiotensin II

Sponsors & Collaborators

  • La Jolla Pharmaceutical Company

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245528 on ClinicalTrials.gov